Caladrius Biosciences
Leading development and manufacturing partner to the cell therapy industry. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€46—69m (Dealroom.co estimates Sep 2016.)
Share price
$4.16 CLBS
River Falls Wisconsin (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
$11.0m | Post IPO Equity | ||
N/A | $38.0m | Post IPO Equity | |
N/A | $12.6m | Late VC | |
$1.9m | Grant | ||
N/A | $5.0m | Post IPO Equity | |
N/A | $25.0m | Post IPO Equity | |
* | N/A | $2.3m | Post IPO Debt |
* | N/A | Merger | |
Total Funding | €13.2m |
Recent News about Caladrius Biosciences
EditMore about Caladrius Biosciencesinfo icon
EditCaladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.